Answers are grounded in this paper and cite their sources.
A better knowledge of the non-commercial clinical research landscape and its challenges and requirements is needed to make drugs-especially those with less commercial gain-accessible to rare diseases patients. Better information about existing resources like research infrastructures, clinical research programs, and counseling mechanisms is needed to support and guide clinicians through the many challenges associated to the set-up of academic-sponsored multinational trials.
No takes yet. Share an insight, caveat, or question.
Álamo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: